Onconova Therapeutics Appoints Drs. Peter Atadja and : vimar

Onconova Therapeutics Appoints Drs. Peter Atadja and

NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company...

Related Keywords

Kumasi , Ashanti , Ghana , China , United States , United Kingdom , London , City Of , British , Trafford Clarke , Mark Guerin , Stevenm Fruchtman , Peter Atadja , Bruce Mackle , Eli Lilly , Kumasi University Of Science , Company Contact , Sandbox Innovation Fund Program , Nasdaq , University Of Liverpool , Innovation Board Of The Association , Novartis Pharmaceuticals , Research Directors Group , European Union Innovative Medicine Initiative , Lifesci Advisors , Company Board Of Directors , United Kingdom Research , Hebrew University , Imperial College , Drug Discovery Translational Research , Development Site Head , Company Ltd , University Of Calgary , Securities Exchange , Onconova Therapeutics Inc , Eli Lilly European Federation Of Pharmaceutical Industries , Chief Executive Officer , Chief Scientific Officer , Commbio Therapeutics , Executive Director , Drug Discovery , Award Winner , Kumasi University , Managing Director , European Federation , Pharmaceutical Industries , Union Innovative Medicine Initiative , Board Member , Innovation Board , British Pharmaceutical , Innovation Fund , Onconova Therapeutics , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Annual Report , Sci Advisors , Nasdaq Ontx , Nc , Ntx Onconova Narazaciclib , Biotechnology , Dk4 6 Ark5 Inhibitor , Nsclc , Deb Associated Scc ,

© 2025 Vimarsana